SundrugLtd（9989）株式概要サンドラッグは日本でドラッグストア事業を行っている。 詳細9989 ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績2/6財務の健全性5/6配当金4/6報酬収益は年間4.93%増加すると予測されています 過去5年間の収益は年間6.6%増加しました。 アナリストらは、株価が25.2%上昇するだろうとほぼ一致している。 リスク分析3.48%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見る9989 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥3.79k0.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01t2016201920222025202620282031Revenue JP¥1.1tEarnings JP¥39.8bAdvancedSet Fair ValueView all narrativesSundrug Co.,Ltd. 競合他社COSMOS PharmaceuticalSymbol: TSE:3349Market cap: JP¥475.1bSugi HoldingsLtdSymbol: TSE:7649Market cap: JP¥567.7bMatsukiyoCocokaraSymbol: TSE:3088Market cap: JP¥917.4bCreate SD HoldingsSymbol: TSE:3148Market cap: JP¥209.3b価格と性能株価の高値、安値、推移の概要SundrugLtd過去の株価現在の株価JP¥3,792.0052週高値JP¥4,883.0052週安値JP¥3,526.00ベータ0.111ヶ月の変化2.05%3ヶ月変化-3.22%1年変化-14.03%3年間の変化-10.84%5年間の変化5.63%IPOからの変化589.74%最新ニュースお知らせ • May 29Sundrug Co.,Ltd. to Report Q1, 2027 Results on Aug 14, 2026Sundrug Co.,Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026Reported Earnings • May 20Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: JP¥268 (up from JP¥263 in FY 2025). Revenue: JP¥842.5b (up 5.1% from FY 2025). Net income: JP¥31.4b (up 2.1% from FY 2025). Profit margin: 3.7% (down from 3.8% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.0%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026.お知らせ • May 09Sundrug Co.,Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Sundrug Co.,Ltd. announced that they will report fiscal year 2026 results on May 15, 2026Upcoming Dividend • Mar 23Upcoming dividend of JP¥66.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 23 June 2026. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).分析記事 • Feb 15Earnings Miss: Sundrug Co.,Ltd. Missed EPS By 7.9% And Analysts Are Revising Their ForecastsSundrug Co.,Ltd. ( TSE:9989 ) last week reported its latest third-quarter results, which makes it a good time for...最新情報をもっと見るRecent updatesお知らせ • May 29Sundrug Co.,Ltd. to Report Q1, 2027 Results on Aug 14, 2026Sundrug Co.,Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026Reported Earnings • May 20Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: JP¥268 (up from JP¥263 in FY 2025). Revenue: JP¥842.5b (up 5.1% from FY 2025). Net income: JP¥31.4b (up 2.1% from FY 2025). Profit margin: 3.7% (down from 3.8% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.0%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026.お知らせ • May 09Sundrug Co.,Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Sundrug Co.,Ltd. announced that they will report fiscal year 2026 results on May 15, 2026Upcoming Dividend • Mar 23Upcoming dividend of JP¥66.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 23 June 2026. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).分析記事 • Feb 15Earnings Miss: Sundrug Co.,Ltd. Missed EPS By 7.9% And Analysts Are Revising Their ForecastsSundrug Co.,Ltd. ( TSE:9989 ) last week reported its latest third-quarter results, which makes it a good time for...Reported Earnings • Feb 14Third quarter 2026 earnings: EPS misses analyst expectationsThird quarter 2026 results: EPS: JP¥76.61 (down from JP¥81.73 in 3Q 2025). Revenue: JP¥217.3b (up 4.5% from 3Q 2025). Net income: JP¥8.96b (down 6.3% from 3Q 2025). Profit margin: 4.1% (down from 4.6% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.9%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.分析記事 • Feb 09Should You Be Adding SundrugLtd (TSE:9989) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Jan 09Investor Optimism Abounds Sundrug Co.,Ltd. (TSE:9989) But Growth Is LackingWith a median price-to-earnings (or "P/E") ratio of close to 15x in Japan, you could be forgiven for feeling...分析記事 • Dec 17Here's Why SundrugLtd (TSE:9989) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Declared Dividend • Dec 02First half dividend of JP¥66.00 announcedShareholders will receive a dividend of JP¥66.00. Ex-date: 30th March 2026 Payment date: 23rd June 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (48% earnings payout ratio) but not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Nov 29Sundrug Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026Sundrug Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026Reported Earnings • Nov 18Second quarter 2026 earnings: EPS exceeds analyst expectationsSecond quarter 2026 results: EPS: JP¥62.62 (up from JP¥59.68 in 2Q 2025). Revenue: JP¥210.7b (up 4.8% from 2Q 2025). Net income: JP¥7.33b (up 4.9% from 2Q 2025). Profit margin: 3.5% (in line with 2Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.0%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 4% per year.分析記事 • Oct 28SundrugLtd (TSE:9989) Will Be Hoping To Turn Its Returns On Capital AroundThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...Upcoming Dividend • Sep 22Upcoming dividend of JP¥65.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 10 December 2025. Payout ratio is a comfortable 48% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%).お知らせ • Sep 02Sundrug Co.,Ltd. to Report Q2, 2026 Results on Nov 14, 2025Sundrug Co.,Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025分析記事 • Sep 01Is SundrugLtd (TSE:9989) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 17The Sundrug Co.,Ltd. (TSE:9989) First-Quarter Results Are Out And Analysts Have Published New ForecastsTSE:9989 1 Year Share Price vs Fair Value Explore SundrugLtd's Fair Values from the Community and select yours Sundrug...Reported Earnings • Aug 15First quarter 2026 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2026 results: EPS: JP¥67.92 (up from JP¥62.33 in 1Q 2025). Revenue: JP¥207.7b (up 6.7% from 1Q 2025). Net income: JP¥7.94b (up 9.0% from 1Q 2025). Profit margin: 3.8% (up from 3.7% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 11% per year.分析記事 • Jul 10Sundrug Co.,Ltd. (TSE:9989) Investors Are Less Pessimistic Than ExpectedSundrug Co.,Ltd.'s ( TSE:9989 ) price-to-earnings (or "P/E") ratio of 17.1x might make it look like a sell right now...Declared Dividend • Jul 09Final dividend of JP¥65.00 announcedShareholders will receive a dividend of JP¥65.00. Ex-date: 29th September 2025 Payment date: 10th December 2025 Dividend yield will be 2.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (222% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jun 24Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: JP¥263 (up from JP¥249 in FY 2024). Revenue: JP¥801.8b (up 6.7% from FY 2024). Net income: JP¥30.8b (up 5.6% from FY 2024). Profit margin: 3.8% (down from 3.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 15% per year.お知らせ • May 31Sundrug Co.,Ltd. to Report Q1, 2026 Results on Aug 14, 2025Sundrug Co.,Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • May 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: JP¥263 (up from JP¥249 in FY 2024). Revenue: JP¥801.8b (up 6.7% from FY 2024). Net income: JP¥30.8b (up 5.6% from FY 2024). Profit margin: 3.8% (down from 3.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 20, 2025Sundrug Co.,Ltd., Annual General Meeting, Jun 20, 2025.分析記事 • Apr 02Here's Why SundrugLtd (TSE:9989) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Upcoming Dividend • Mar 21Upcoming dividend of JP¥65.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 June 2025. Payout ratio is a comfortable 22% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.7%).分析記事 • Mar 03SundrugLtd (TSE:9989) Will Pay A Dividend Of ¥65.00Sundrug Co.,Ltd.'s ( TSE:9989 ) investors are due to receive a payment of ¥65.00 per share on 24th of June. This will...お知らせ • Mar 01Sundrug Co.,Ltd. to Report Fiscal Year 2025 Results on May 15, 2025Sundrug Co.,Ltd. announced that they will report fiscal year 2025 results on May 15, 2025分析記事 • Feb 18Sundrug Co.,Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsInvestors in Sundrug Co.,Ltd. ( TSE:9989 ) had a good week, as its shares rose 2.8% to close at JP¥4,197 following the...Reported Earnings • Feb 16Third quarter 2025 earnings: EPS exceeds analyst expectationsThird quarter 2025 results: EPS: JP¥81.73 (up from JP¥74.62 in 3Q 2024). Revenue: JP¥208.0b (up 7.1% from 3Q 2024). Net income: JP¥9.56b (up 9.5% from 3Q 2024). Profit margin: 4.6% (up from 4.5% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year and the company’s share price has also increased by 9% per year.Buy Or Sell Opportunity • Feb 06Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 8.6% to JP¥4,076. The fair value is estimated to be JP¥3,391, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 8.6%. For the next 3 years, revenue is forecast to grow by 6.1% per annum. Earnings are also forecast to grow by 6.1% per annum over the same time period.分析記事 • Jan 21Are Sundrug Co.,Ltd. (TSE:9989) Investors Paying Above The Intrinsic Value?Key Insights SundrugLtd's estimated fair value is JP¥3,391 based on 2 Stage Free Cash Flow to Equity SundrugLtd's...Buy Or Sell Opportunity • Jan 07Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at JP¥4,093. The fair value is estimated to be JP¥3,388, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 8.6%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings are also forecast to grow by 5.7% per annum over the same time period.分析記事 • Dec 25SundrugLtd (TSE:9989) Has Announced A Dividend Of ¥65.00Sundrug Co.,Ltd. ( TSE:9989 ) will pay a dividend of ¥65.00 on the 24th of June. This takes the dividend yield to 3.3...分析記事 • Dec 11SundrugLtd's (TSE:9989) Dividend Will Be ¥65.00Sundrug Co.,Ltd.'s ( TSE:9989 ) investors are due to receive a payment of ¥65.00 per share on 24th of June. This makes...Declared Dividend • Dec 11First half dividend of JP¥65.00 announcedShareholders will receive a dividend of JP¥65.00. Ex-date: 28th March 2025 Payment date: 24th June 2025 Dividend yield will be 3.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (dividend approximately 7x free cash flows). The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover.分析記事 • Dec 09Is SundrugLtd (TSE:9989) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...お知らせ • Dec 03Sundrug Co.,Ltd. to Report Q3, 2025 Results on Feb 14, 2025Sundrug Co.,Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025Reported Earnings • Nov 20Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: EPS: JP¥59.68 (down from JP¥61.17 in 2Q 2024). Revenue: JP¥201.0b (up 6.0% from 2Q 2024). Net income: JP¥6.98b (down 2.4% from 2Q 2024). Profit margin: 3.5% (down from 3.8% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.7%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.分析記事 • Nov 18Here's Why We Think SundrugLtd (TSE:9989) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Nov 05Investors Could Be Concerned With SundrugLtd's (TSE:9989) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Sep 25Sundrug Co.,Ltd.'s (TSE:9989) Intrinsic Value Is Potentially 31% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, SundrugLtd fair value estimate is JP¥5,560 SundrugLtd's...Upcoming Dividend • Sep 20Upcoming dividend of JP¥65.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 45% but the company is paying out more than the cash it is generating. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.6%).分析記事 • Sep 11Sundrug Co.,Ltd.'s (TSE:9989) Business Is Yet to Catch Up With Its Share PriceWith a price-to-earnings (or "P/E") ratio of 16.6x Sundrug Co.,Ltd. ( TSE:9989 ) may be sending bearish signals at the...分析記事 • Aug 29SundrugLtd's (TSE:9989) Upcoming Dividend Will Be Larger Than Last Year'sThe board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will be paying its dividend of ¥65.00 on the 4th of...お知らせ • Aug 28Sundrug Co.,Ltd. to Report Q2, 2025 Results on Nov 14, 2024Sundrug Co.,Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 19First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: JP¥62.33 (up from JP¥59.01 in 1Q 2024). Revenue: JP¥194.6b (up 6.8% from 1Q 2024). Net income: JP¥7.29b (up 5.7% from 1Q 2024). Profit margin: 3.7% (down from 3.8% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year.分析記事 • Jul 26SundrugLtd (TSE:9989) Will Pay A Larger Dividend Than Last Year At ¥65.00The board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will be paying its dividend of ¥65.00 on the 4th of...分析記事 • Jul 12SundrugLtd (TSE:9989) Will Pay A Larger Dividend Than Last Year At ¥65.00The board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will be paying its dividend of ¥65.00 on the 4th of...Declared Dividend • Jul 11Final dividend increased to JP¥65.00Dividend of JP¥65.00 is 14% higher than last year. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 3.1%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but not covered by cash flows (dividend approximately 5x free cash flows). The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.分析記事 • Jun 28Analyst Estimates: Here's What Brokers Think Of Sundrug Co.,Ltd. (TSE:9989) After Its Yearly ReportInvestors in Sundrug Co.,Ltd. ( TSE:9989 ) had a good week, as its shares rose 3.4% to close at JP¥4,054 following the...Reported Earnings • Jun 28Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥249 (up from JP¥220 in FY 2023). Revenue: JP¥751.8b (up 8.9% from FY 2023). Net income: JP¥29.1b (up 13% from FY 2023). Profit margin: 3.9% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.分析記事 • Jun 06SundrugLtd (TSE:9989) Ticks All The Boxes When It Comes To Earnings GrowthIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...お知らせ • Jun 02Sundrug Co.,Ltd. to Report Q1, 2025 Results on Aug 14, 2024Sundrug Co.,Ltd. announced that they will report Q1, 2025 results on Aug 14, 2024Reported Earnings • May 20Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥249 (up from JP¥220 in FY 2023). Revenue: JP¥751.8b (up 8.9% from FY 2023). Net income: JP¥29.1b (up 13% from FY 2023). Profit margin: 3.9% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.お知らせ • May 17Sundrug Co.,Ltd., Annual General Meeting, Jun 21, 2024Sundrug Co.,Ltd., Annual General Meeting, Jun 21, 2024.分析記事 • May 11Sundrug Co.,Ltd.'s (TSE:9989) Share Price Not Quite Adding UpWhen close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 14x, you may consider...分析記事 • Apr 10Be Wary Of SundrugLtd (TSE:9989) And Its Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Buy Or Sell Opportunity • Mar 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 8.6% to JP¥4,870. The fair value is estimated to be JP¥4,027, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 3.2%. For the next 3 years, revenue is forecast to grow by 6.4% per annum. Earnings are also forecast to grow by 8.0% per annum over the same time period.Upcoming Dividend • Mar 21Upcoming dividend of JP¥57.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 June 2024. Payout ratio is a comfortable 44% but the company is paying out more than the cash it is generating. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (1.5%).分析記事 • Mar 11SundrugLtd (TSE:9989) Will Pay A Dividend Of ¥57.00The board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will pay a dividend on the 26th of June, with...Buy Or Sell Opportunity • Mar 07Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 7.1% to JP¥4,846. The fair value is estimated to be JP¥4,027, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 3.2%. For the next 3 years, revenue is forecast to grow by 6.4% per annum. Earnings are also forecast to grow by 8.0% per annum over the same time period.お知らせ • Mar 02Sundrug Co.,Ltd. to Report Fiscal Year 2024 Results on May 15, 2024Sundrug Co.,Ltd. announced that they will report fiscal year 2024 results on May 15, 2024Reported Earnings • Feb 16Third quarter 2024 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2024 results: EPS: JP¥74.62 (up from JP¥65.36 in 3Q 2023). Revenue: JP¥194.3b (up 7.7% from 3Q 2023). Net income: JP¥8.73b (up 14% from 3Q 2023). Profit margin: 4.5% (up from 4.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.お知らせ • Nov 27Sundrug Co.,Ltd. to Report Q3, 2024 Results on Feb 14, 2024Sundrug Co.,Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024Reported Earnings • Nov 17Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: EPS: JP¥61.17 (up from JP¥54.94 in 2Q 2023). Revenue: JP¥189.6b (up 9.7% from 2Q 2023). Net income: JP¥7.15b (up 11% from 2Q 2023). Profit margin: 3.8% (up from 3.7% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 1% per year.Upcoming Dividend • Sep 21Upcoming dividend of JP¥57.00 per share at 2.7% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 44% and the cash payout ratio is 89%. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (1.6%).お知らせ • Aug 27Sundrug Co.,Ltd. to Report Q2, 2024 Results on Nov 14, 2023Sundrug Co.,Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023Reported Earnings • Aug 12First quarter 2024 earnings released: EPS: JP¥59.01 (vs JP¥53.86 in 1Q 2023)First quarter 2024 results: EPS: JP¥59.01 (up from JP¥53.86 in 1Q 2023). Revenue: JP¥182.1b (up 9.4% from 1Q 2023). Net income: JP¥6.90b (up 9.6% from 1Q 2023). Profit margin: 3.8% (in line with 1Q 2023). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 3% per year.お知らせ • May 31Sundrug Co.,Ltd. to Report Q1, 2024 Results on Aug 10, 2023Sundrug Co.,Ltd. announced that they will report Q1, 2024 results on Aug 10, 2023お知らせ • May 17Sundrug Co.,Ltd., Annual General Meeting, Jun 23, 2023Sundrug Co.,Ltd., Annual General Meeting, Jun 23, 2023.Reported Earnings • May 17Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥220 (up from JP¥204 in FY 2022). Revenue: JP¥690.5b (up 6.4% from FY 2022). Net income: JP¥25.7b (up 7.8% from FY 2022). Profit margin: 3.7% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.6%. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Mar 23Upcoming dividend of JP¥50.00 per share at 2.8% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).Reported Earnings • Feb 17Third quarter 2023 earnings released: EPS: JP¥65.36 (vs JP¥56.01 in 3Q 2022)Third quarter 2023 results: EPS: JP¥65.36 (up from JP¥56.01 in 3Q 2022). Revenue: JP¥180.3b (up 9.4% from 3Q 2022). Net income: JP¥7.64b (up 17% from 3Q 2022). Profit margin: 4.2% (up from 4.0% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 3% per year.お知らせ • Nov 30Sundrug Co.,Ltd. to Report Q3, 2023 Results on Feb 14, 2023Sundrug Co.,Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. No independent directors (9 non-independent directors). CEO, President & Representative Director Koji Sadakata was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Sep 22Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.6%).お知らせ • Sep 02Sundrug Co.,Ltd. (TSE:9989) agreed to acquire Daiya, K.K. from Shintaro Ito, Ichiban Co., Ltd and others.Sundrug Co.,Ltd. (TSE:9989) agreed to acquire Daiya, K.K. from Shintaro Ito, Ichiban Co., Ltd and others on September 1, 2022. For the period ended February 2022, Daiya reported Total assets of 12 billion, net worth of 2.5 billion, Revenue of 26.6 billion, Operating income of 216 million, and Net income of 418 million. The acquisition is expected to close on October 3, 2022.お知らせ • Aug 28Sundrug Co.,Ltd. to Report Q2, 2023 Results on Nov 14, 2022Sundrug Co.,Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022Reported Earnings • Aug 15First quarter 2023 earnings released: EPS: JP¥53.86 (vs JP¥58.18 in 1Q 2022)First quarter 2023 results: EPS: JP¥53.86 (down from JP¥58.18 in 1Q 2022). Revenue: JP¥166.5b (up 1.4% from 1Q 2022). Net income: JP¥6.30b (down 7.4% from 1Q 2022). Profit margin: 3.8% (down from 4.1% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.3%, compared to a 11% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.お知らせ • May 29Sundrug Co.,Ltd. to Report Q1, 2023 Results on Aug 12, 2022Sundrug Co.,Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022Reported Earnings • May 16Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: JP¥204 (down from JP¥217 in FY 2021). Revenue: JP¥648.7b (up 2.3% from FY 2021). Net income: JP¥23.9b (down 5.8% from FY 2021). Profit margin: 3.7% (down from 4.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 6.5%, compared to a 21% growth forecast for the retail industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 2% per year.お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 25, 2022Sundrug Co.,Ltd., Annual General Meeting, Jun 25, 2022.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. No independent directors (9 non-independent directors). CEO, President & Representative Director Koji Sadakata was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 08Sundrug Co.,Ltd. to Report Fiscal Year 2022 Results on May 13, 2022Sundrug Co.,Ltd. announced that they will report fiscal year 2022 results on May 13, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (1.6%).Reported Earnings • Feb 18Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: EPS: JP¥56.01 (down from JP¥61.99 in 3Q 2021). Revenue: JP¥164.9b (flat on 3Q 2021). Net income: JP¥6.55b (down 9.6% from 3Q 2021). Profit margin: 4.0% (down from 4.4% in 3Q 2021). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 5.9%, compared to a 14% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 3% per year.Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS JP¥48.36 (vs JP¥54.98 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥162.6b (up 1.8% from 2Q 2021). Net income: JP¥5.65b (down 12% from 2Q 2021). Profit margin: 3.5% (down from 4.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 14 December 2021. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (3.0%). Higher than average of industry peers (1.4%).Reported Earnings • Aug 15First quarter 2022 earnings released: EPS JP¥58.18 (vs JP¥60.32 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: JP¥164.2b (up 4.7% from 1Q 2021). Net income: JP¥6.80b (down 3.5% from 1Q 2021). Profit margin: 4.1% (down from 4.5% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.Reported Earnings • May 18Full year 2021 earnings released: EPS JP¥217 (vs JP¥203 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥634.3b (up 2.7% from FY 2020). Net income: JP¥25.3b (up 6.9% from FY 2020). Profit margin: 4.0% (up from 3.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Upcoming Dividend • Mar 23Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 22 June 2021. Trailing yield: 1.7%. Lower than top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (1.4%).お知らせ • Mar 04Sundrug Co.,Ltd. to Report Fiscal Year 2021 Results on May 14, 2021Sundrug Co.,Ltd. announced that they will report fiscal year 2021 results on May 14, 2021Is New 90 Day High Low • Feb 17New 90-day low: JP¥4,020The company is down 4.0% from its price of JP¥4,180 on 19 November 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥5,074 per share.Reported Earnings • Feb 12Third quarter 2021 earnings released: EPS JP¥61.99 (vs JP¥46.72 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥164.3b (up 11% from 3Q 2020). Net income: JP¥7.25b (up 33% from 3Q 2020). Profit margin: 4.4% (up from 3.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.Analyst Estimate Surprise Post Earnings • Feb 12Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.02%. Earnings per share (EPS) also missed analyst estimates by 5.7%. Over the next year, revenue is forecast to grow 4.5%, compared to a 8.4% growth forecast for the Consumer Retailing industry in Japan.Is New 90 Day High Low • Dec 04New 90-day high: JP¥4,515The company is up 16% from its price of JP¥3,905 on 04 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥4,276 per share.お知らせ • Nov 29Sundrug Co.,Ltd. to Report Q3, 2021 Results on Feb 10, 2021Sundrug Co.,Ltd. announced that they will report Q3, 2021 results on Feb 10, 2021株主還元9989JP Consumer RetailingJP 市場7D-1.3%-2.3%4.7%1Y-14.0%-11.4%46.9%株主還元を見る業界別リターン: 9989過去 1 年間で-11.4 % の収益を上げたJP Consumer Retailing業界を下回りました。リターン対市場: 9989は、過去 1 年間で46.9 % のリターンを上げたJP市場を下回りました。価格変動Is 9989's price volatile compared to industry and market?9989 volatility9989 Average Weekly Movement2.2%Consumer Retailing Industry Average Movement3.3%Market Average Movement4.6%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.3%安定した株価: 9989 、 JP市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 9989の 週次ボラティリティ ( 2% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19577,145Hiroshi Sadakatawww.sundrug.co.jpサンドラッグは日本でドラッグストア事業を行っている。ドラッグストア事業とディスカウントストア事業を行っている。ドラッグストア事業は主に医薬品、化粧品、日用品を販売している。ディスカウントストア事業は食品と日用品を扱う。同社は1957年に設立され、日本の府中に本社を置く。もっと見るSundrug Co.,Ltd. 基礎のまとめSundrugLtd の収益と売上を時価総額と比較するとどうか。9989 基礎統計学時価総額JP¥443.60b収益（TTM）JP¥31.39b売上高(TTM)JP¥842.51b14.1xPER（株価収益率0.5xP/Sレシオ9989 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計9989 損益計算書（TTM）収益JP¥842.51b売上原価JP¥626.34b売上総利益JP¥216.17bその他の費用JP¥184.78b収益JP¥31.39b直近の収益報告Mar 31, 2026次回決算日Aug 14, 2026一株当たり利益（EPS）268.35グロス・マージン25.66%純利益率3.73%有利子負債／自己資本比率16.9%9989 の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.5%現在の配当利回り49%配当性向9989 配当は確実ですか？9989 配当履歴とベンチマークを見る9989 、いつまでに購入すれば配当金を受け取れますか？SundrugLtd 配当日配当落ち日Mar 30 2026配当支払日Jun 29 2026配当落ちまでの日数84 days配当支払日までの日数7 days9989 配当は確実ですか？9989 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/20 18:49終値2026/06/19 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sundrug Co.,Ltd. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Daisuke MatsumotoBarclaysArashi NishizawaBofA Global ResearchMayumi OginoCitigroup Inc13 その他のアナリストを表示
お知らせ • May 29Sundrug Co.,Ltd. to Report Q1, 2027 Results on Aug 14, 2026Sundrug Co.,Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026
Reported Earnings • May 20Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: JP¥268 (up from JP¥263 in FY 2025). Revenue: JP¥842.5b (up 5.1% from FY 2025). Net income: JP¥31.4b (up 2.1% from FY 2025). Profit margin: 3.7% (down from 3.8% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.0%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026.
お知らせ • May 09Sundrug Co.,Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Sundrug Co.,Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
Upcoming Dividend • Mar 23Upcoming dividend of JP¥66.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 23 June 2026. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).
分析記事 • Feb 15Earnings Miss: Sundrug Co.,Ltd. Missed EPS By 7.9% And Analysts Are Revising Their ForecastsSundrug Co.,Ltd. ( TSE:9989 ) last week reported its latest third-quarter results, which makes it a good time for...
お知らせ • May 29Sundrug Co.,Ltd. to Report Q1, 2027 Results on Aug 14, 2026Sundrug Co.,Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026
Reported Earnings • May 20Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: JP¥268 (up from JP¥263 in FY 2025). Revenue: JP¥842.5b (up 5.1% from FY 2025). Net income: JP¥31.4b (up 2.1% from FY 2025). Profit margin: 3.7% (down from 3.8% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.0%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026.
お知らせ • May 09Sundrug Co.,Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Sundrug Co.,Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
Upcoming Dividend • Mar 23Upcoming dividend of JP¥66.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 23 June 2026. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).
分析記事 • Feb 15Earnings Miss: Sundrug Co.,Ltd. Missed EPS By 7.9% And Analysts Are Revising Their ForecastsSundrug Co.,Ltd. ( TSE:9989 ) last week reported its latest third-quarter results, which makes it a good time for...
Reported Earnings • Feb 14Third quarter 2026 earnings: EPS misses analyst expectationsThird quarter 2026 results: EPS: JP¥76.61 (down from JP¥81.73 in 3Q 2025). Revenue: JP¥217.3b (up 4.5% from 3Q 2025). Net income: JP¥8.96b (down 6.3% from 3Q 2025). Profit margin: 4.1% (down from 4.6% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.9%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.
分析記事 • Feb 09Should You Be Adding SundrugLtd (TSE:9989) To Your Watchlist Today?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
分析記事 • Jan 09Investor Optimism Abounds Sundrug Co.,Ltd. (TSE:9989) But Growth Is LackingWith a median price-to-earnings (or "P/E") ratio of close to 15x in Japan, you could be forgiven for feeling...
分析記事 • Dec 17Here's Why SundrugLtd (TSE:9989) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Declared Dividend • Dec 02First half dividend of JP¥66.00 announcedShareholders will receive a dividend of JP¥66.00. Ex-date: 30th March 2026 Payment date: 23rd June 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (48% earnings payout ratio) but not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 29Sundrug Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026Sundrug Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026
Reported Earnings • Nov 18Second quarter 2026 earnings: EPS exceeds analyst expectationsSecond quarter 2026 results: EPS: JP¥62.62 (up from JP¥59.68 in 2Q 2025). Revenue: JP¥210.7b (up 4.8% from 2Q 2025). Net income: JP¥7.33b (up 4.9% from 2Q 2025). Profit margin: 3.5% (in line with 2Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.0%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 4% per year.
分析記事 • Oct 28SundrugLtd (TSE:9989) Will Be Hoping To Turn Its Returns On Capital AroundThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Upcoming Dividend • Sep 22Upcoming dividend of JP¥65.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 10 December 2025. Payout ratio is a comfortable 48% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%).
お知らせ • Sep 02Sundrug Co.,Ltd. to Report Q2, 2026 Results on Nov 14, 2025Sundrug Co.,Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025
分析記事 • Sep 01Is SundrugLtd (TSE:9989) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Aug 17The Sundrug Co.,Ltd. (TSE:9989) First-Quarter Results Are Out And Analysts Have Published New ForecastsTSE:9989 1 Year Share Price vs Fair Value Explore SundrugLtd's Fair Values from the Community and select yours Sundrug...
Reported Earnings • Aug 15First quarter 2026 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2026 results: EPS: JP¥67.92 (up from JP¥62.33 in 1Q 2025). Revenue: JP¥207.7b (up 6.7% from 1Q 2025). Net income: JP¥7.94b (up 9.0% from 1Q 2025). Profit margin: 3.8% (up from 3.7% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 11% per year.
分析記事 • Jul 10Sundrug Co.,Ltd. (TSE:9989) Investors Are Less Pessimistic Than ExpectedSundrug Co.,Ltd.'s ( TSE:9989 ) price-to-earnings (or "P/E") ratio of 17.1x might make it look like a sell right now...
Declared Dividend • Jul 09Final dividend of JP¥65.00 announcedShareholders will receive a dividend of JP¥65.00. Ex-date: 29th September 2025 Payment date: 10th December 2025 Dividend yield will be 2.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (222% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jun 24Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: JP¥263 (up from JP¥249 in FY 2024). Revenue: JP¥801.8b (up 6.7% from FY 2024). Net income: JP¥30.8b (up 5.6% from FY 2024). Profit margin: 3.8% (down from 3.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 15% per year.
お知らせ • May 31Sundrug Co.,Ltd. to Report Q1, 2026 Results on Aug 14, 2025Sundrug Co.,Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • May 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: JP¥263 (up from JP¥249 in FY 2024). Revenue: JP¥801.8b (up 6.7% from FY 2024). Net income: JP¥30.8b (up 5.6% from FY 2024). Profit margin: 3.8% (down from 3.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 20, 2025Sundrug Co.,Ltd., Annual General Meeting, Jun 20, 2025.
分析記事 • Apr 02Here's Why SundrugLtd (TSE:9989) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Upcoming Dividend • Mar 21Upcoming dividend of JP¥65.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 June 2025. Payout ratio is a comfortable 22% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.7%).
分析記事 • Mar 03SundrugLtd (TSE:9989) Will Pay A Dividend Of ¥65.00Sundrug Co.,Ltd.'s ( TSE:9989 ) investors are due to receive a payment of ¥65.00 per share on 24th of June. This will...
お知らせ • Mar 01Sundrug Co.,Ltd. to Report Fiscal Year 2025 Results on May 15, 2025Sundrug Co.,Ltd. announced that they will report fiscal year 2025 results on May 15, 2025
分析記事 • Feb 18Sundrug Co.,Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsInvestors in Sundrug Co.,Ltd. ( TSE:9989 ) had a good week, as its shares rose 2.8% to close at JP¥4,197 following the...
Reported Earnings • Feb 16Third quarter 2025 earnings: EPS exceeds analyst expectationsThird quarter 2025 results: EPS: JP¥81.73 (up from JP¥74.62 in 3Q 2024). Revenue: JP¥208.0b (up 7.1% from 3Q 2024). Net income: JP¥9.56b (up 9.5% from 3Q 2024). Profit margin: 4.6% (up from 4.5% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year and the company’s share price has also increased by 9% per year.
Buy Or Sell Opportunity • Feb 06Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 8.6% to JP¥4,076. The fair value is estimated to be JP¥3,391, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 8.6%. For the next 3 years, revenue is forecast to grow by 6.1% per annum. Earnings are also forecast to grow by 6.1% per annum over the same time period.
分析記事 • Jan 21Are Sundrug Co.,Ltd. (TSE:9989) Investors Paying Above The Intrinsic Value?Key Insights SundrugLtd's estimated fair value is JP¥3,391 based on 2 Stage Free Cash Flow to Equity SundrugLtd's...
Buy Or Sell Opportunity • Jan 07Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at JP¥4,093. The fair value is estimated to be JP¥3,388, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 8.6%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings are also forecast to grow by 5.7% per annum over the same time period.
分析記事 • Dec 25SundrugLtd (TSE:9989) Has Announced A Dividend Of ¥65.00Sundrug Co.,Ltd. ( TSE:9989 ) will pay a dividend of ¥65.00 on the 24th of June. This takes the dividend yield to 3.3...
分析記事 • Dec 11SundrugLtd's (TSE:9989) Dividend Will Be ¥65.00Sundrug Co.,Ltd.'s ( TSE:9989 ) investors are due to receive a payment of ¥65.00 per share on 24th of June. This makes...
Declared Dividend • Dec 11First half dividend of JP¥65.00 announcedShareholders will receive a dividend of JP¥65.00. Ex-date: 28th March 2025 Payment date: 24th June 2025 Dividend yield will be 3.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (dividend approximately 7x free cash flows). The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
分析記事 • Dec 09Is SundrugLtd (TSE:9989) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
お知らせ • Dec 03Sundrug Co.,Ltd. to Report Q3, 2025 Results on Feb 14, 2025Sundrug Co.,Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025
Reported Earnings • Nov 20Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: EPS: JP¥59.68 (down from JP¥61.17 in 2Q 2024). Revenue: JP¥201.0b (up 6.0% from 2Q 2024). Net income: JP¥6.98b (down 2.4% from 2Q 2024). Profit margin: 3.5% (down from 3.8% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.7%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
分析記事 • Nov 18Here's Why We Think SundrugLtd (TSE:9989) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
分析記事 • Nov 05Investors Could Be Concerned With SundrugLtd's (TSE:9989) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Sep 25Sundrug Co.,Ltd.'s (TSE:9989) Intrinsic Value Is Potentially 31% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, SundrugLtd fair value estimate is JP¥5,560 SundrugLtd's...
Upcoming Dividend • Sep 20Upcoming dividend of JP¥65.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 45% but the company is paying out more than the cash it is generating. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.6%).
分析記事 • Sep 11Sundrug Co.,Ltd.'s (TSE:9989) Business Is Yet to Catch Up With Its Share PriceWith a price-to-earnings (or "P/E") ratio of 16.6x Sundrug Co.,Ltd. ( TSE:9989 ) may be sending bearish signals at the...
分析記事 • Aug 29SundrugLtd's (TSE:9989) Upcoming Dividend Will Be Larger Than Last Year'sThe board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will be paying its dividend of ¥65.00 on the 4th of...
お知らせ • Aug 28Sundrug Co.,Ltd. to Report Q2, 2025 Results on Nov 14, 2024Sundrug Co.,Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 19First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: JP¥62.33 (up from JP¥59.01 in 1Q 2024). Revenue: JP¥194.6b (up 6.8% from 1Q 2024). Net income: JP¥7.29b (up 5.7% from 1Q 2024). Profit margin: 3.7% (down from 3.8% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year.
分析記事 • Jul 26SundrugLtd (TSE:9989) Will Pay A Larger Dividend Than Last Year At ¥65.00The board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will be paying its dividend of ¥65.00 on the 4th of...
分析記事 • Jul 12SundrugLtd (TSE:9989) Will Pay A Larger Dividend Than Last Year At ¥65.00The board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will be paying its dividend of ¥65.00 on the 4th of...
Declared Dividend • Jul 11Final dividend increased to JP¥65.00Dividend of JP¥65.00 is 14% higher than last year. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 3.1%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but not covered by cash flows (dividend approximately 5x free cash flows). The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
分析記事 • Jun 28Analyst Estimates: Here's What Brokers Think Of Sundrug Co.,Ltd. (TSE:9989) After Its Yearly ReportInvestors in Sundrug Co.,Ltd. ( TSE:9989 ) had a good week, as its shares rose 3.4% to close at JP¥4,054 following the...
Reported Earnings • Jun 28Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥249 (up from JP¥220 in FY 2023). Revenue: JP¥751.8b (up 8.9% from FY 2023). Net income: JP¥29.1b (up 13% from FY 2023). Profit margin: 3.9% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.
分析記事 • Jun 06SundrugLtd (TSE:9989) Ticks All The Boxes When It Comes To Earnings GrowthIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
お知らせ • Jun 02Sundrug Co.,Ltd. to Report Q1, 2025 Results on Aug 14, 2024Sundrug Co.,Ltd. announced that they will report Q1, 2025 results on Aug 14, 2024
Reported Earnings • May 20Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥249 (up from JP¥220 in FY 2023). Revenue: JP¥751.8b (up 8.9% from FY 2023). Net income: JP¥29.1b (up 13% from FY 2023). Profit margin: 3.9% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.
お知らせ • May 17Sundrug Co.,Ltd., Annual General Meeting, Jun 21, 2024Sundrug Co.,Ltd., Annual General Meeting, Jun 21, 2024.
分析記事 • May 11Sundrug Co.,Ltd.'s (TSE:9989) Share Price Not Quite Adding UpWhen close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 14x, you may consider...
分析記事 • Apr 10Be Wary Of SundrugLtd (TSE:9989) And Its Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Buy Or Sell Opportunity • Mar 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 8.6% to JP¥4,870. The fair value is estimated to be JP¥4,027, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 3.2%. For the next 3 years, revenue is forecast to grow by 6.4% per annum. Earnings are also forecast to grow by 8.0% per annum over the same time period.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥57.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 June 2024. Payout ratio is a comfortable 44% but the company is paying out more than the cash it is generating. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (1.5%).
分析記事 • Mar 11SundrugLtd (TSE:9989) Will Pay A Dividend Of ¥57.00The board of Sundrug Co.,Ltd. ( TSE:9989 ) has announced that it will pay a dividend on the 26th of June, with...
Buy Or Sell Opportunity • Mar 07Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 7.1% to JP¥4,846. The fair value is estimated to be JP¥4,027, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 3.2%. For the next 3 years, revenue is forecast to grow by 6.4% per annum. Earnings are also forecast to grow by 8.0% per annum over the same time period.
お知らせ • Mar 02Sundrug Co.,Ltd. to Report Fiscal Year 2024 Results on May 15, 2024Sundrug Co.,Ltd. announced that they will report fiscal year 2024 results on May 15, 2024
Reported Earnings • Feb 16Third quarter 2024 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2024 results: EPS: JP¥74.62 (up from JP¥65.36 in 3Q 2023). Revenue: JP¥194.3b (up 7.7% from 3Q 2023). Net income: JP¥8.73b (up 14% from 3Q 2023). Profit margin: 4.5% (up from 4.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.
お知らせ • Nov 27Sundrug Co.,Ltd. to Report Q3, 2024 Results on Feb 14, 2024Sundrug Co.,Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024
Reported Earnings • Nov 17Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: EPS: JP¥61.17 (up from JP¥54.94 in 2Q 2023). Revenue: JP¥189.6b (up 9.7% from 2Q 2023). Net income: JP¥7.15b (up 11% from 2Q 2023). Profit margin: 3.8% (up from 3.7% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 1% per year.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥57.00 per share at 2.7% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 44% and the cash payout ratio is 89%. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (1.6%).
お知らせ • Aug 27Sundrug Co.,Ltd. to Report Q2, 2024 Results on Nov 14, 2023Sundrug Co.,Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023
Reported Earnings • Aug 12First quarter 2024 earnings released: EPS: JP¥59.01 (vs JP¥53.86 in 1Q 2023)First quarter 2024 results: EPS: JP¥59.01 (up from JP¥53.86 in 1Q 2023). Revenue: JP¥182.1b (up 9.4% from 1Q 2023). Net income: JP¥6.90b (up 9.6% from 1Q 2023). Profit margin: 3.8% (in line with 1Q 2023). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 3% per year.
お知らせ • May 31Sundrug Co.,Ltd. to Report Q1, 2024 Results on Aug 10, 2023Sundrug Co.,Ltd. announced that they will report Q1, 2024 results on Aug 10, 2023
お知らせ • May 17Sundrug Co.,Ltd., Annual General Meeting, Jun 23, 2023Sundrug Co.,Ltd., Annual General Meeting, Jun 23, 2023.
Reported Earnings • May 17Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥220 (up from JP¥204 in FY 2022). Revenue: JP¥690.5b (up 6.4% from FY 2022). Net income: JP¥25.7b (up 7.8% from FY 2022). Profit margin: 3.7% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.6%. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥50.00 per share at 2.8% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%).
Reported Earnings • Feb 17Third quarter 2023 earnings released: EPS: JP¥65.36 (vs JP¥56.01 in 3Q 2022)Third quarter 2023 results: EPS: JP¥65.36 (up from JP¥56.01 in 3Q 2022). Revenue: JP¥180.3b (up 9.4% from 3Q 2022). Net income: JP¥7.64b (up 17% from 3Q 2022). Profit margin: 4.2% (up from 4.0% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 3% per year.
お知らせ • Nov 30Sundrug Co.,Ltd. to Report Q3, 2023 Results on Feb 14, 2023Sundrug Co.,Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. No independent directors (9 non-independent directors). CEO, President & Representative Director Koji Sadakata was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.6%).
お知らせ • Sep 02Sundrug Co.,Ltd. (TSE:9989) agreed to acquire Daiya, K.K. from Shintaro Ito, Ichiban Co., Ltd and others.Sundrug Co.,Ltd. (TSE:9989) agreed to acquire Daiya, K.K. from Shintaro Ito, Ichiban Co., Ltd and others on September 1, 2022. For the period ended February 2022, Daiya reported Total assets of 12 billion, net worth of 2.5 billion, Revenue of 26.6 billion, Operating income of 216 million, and Net income of 418 million. The acquisition is expected to close on October 3, 2022.
お知らせ • Aug 28Sundrug Co.,Ltd. to Report Q2, 2023 Results on Nov 14, 2022Sundrug Co.,Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022
Reported Earnings • Aug 15First quarter 2023 earnings released: EPS: JP¥53.86 (vs JP¥58.18 in 1Q 2022)First quarter 2023 results: EPS: JP¥53.86 (down from JP¥58.18 in 1Q 2022). Revenue: JP¥166.5b (up 1.4% from 1Q 2022). Net income: JP¥6.30b (down 7.4% from 1Q 2022). Profit margin: 3.8% (down from 4.1% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.3%, compared to a 11% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
お知らせ • May 29Sundrug Co.,Ltd. to Report Q1, 2023 Results on Aug 12, 2022Sundrug Co.,Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022
Reported Earnings • May 16Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: JP¥204 (down from JP¥217 in FY 2021). Revenue: JP¥648.7b (up 2.3% from FY 2021). Net income: JP¥23.9b (down 5.8% from FY 2021). Profit margin: 3.7% (down from 4.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 6.5%, compared to a 21% growth forecast for the retail industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 2% per year.
お知らせ • May 15Sundrug Co.,Ltd., Annual General Meeting, Jun 25, 2022Sundrug Co.,Ltd., Annual General Meeting, Jun 25, 2022.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. No independent directors (9 non-independent directors). CEO, President & Representative Director Koji Sadakata was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 08Sundrug Co.,Ltd. to Report Fiscal Year 2022 Results on May 13, 2022Sundrug Co.,Ltd. announced that they will report fiscal year 2022 results on May 13, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (1.6%).
Reported Earnings • Feb 18Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: EPS: JP¥56.01 (down from JP¥61.99 in 3Q 2021). Revenue: JP¥164.9b (flat on 3Q 2021). Net income: JP¥6.55b (down 9.6% from 3Q 2021). Profit margin: 4.0% (down from 4.4% in 3Q 2021). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 5.9%, compared to a 14% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 3% per year.
Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS JP¥48.36 (vs JP¥54.98 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥162.6b (up 1.8% from 2Q 2021). Net income: JP¥5.65b (down 12% from 2Q 2021). Profit margin: 3.5% (down from 4.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 14 December 2021. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (3.0%). Higher than average of industry peers (1.4%).
Reported Earnings • Aug 15First quarter 2022 earnings released: EPS JP¥58.18 (vs JP¥60.32 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: JP¥164.2b (up 4.7% from 1Q 2021). Net income: JP¥6.80b (down 3.5% from 1Q 2021). Profit margin: 4.1% (down from 4.5% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year.
Reported Earnings • May 18Full year 2021 earnings released: EPS JP¥217 (vs JP¥203 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥634.3b (up 2.7% from FY 2020). Net income: JP¥25.3b (up 6.9% from FY 2020). Profit margin: 4.0% (up from 3.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 22 June 2021. Trailing yield: 1.7%. Lower than top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (1.4%).
お知らせ • Mar 04Sundrug Co.,Ltd. to Report Fiscal Year 2021 Results on May 14, 2021Sundrug Co.,Ltd. announced that they will report fiscal year 2021 results on May 14, 2021
Is New 90 Day High Low • Feb 17New 90-day low: JP¥4,020The company is down 4.0% from its price of JP¥4,180 on 19 November 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥5,074 per share.
Reported Earnings • Feb 12Third quarter 2021 earnings released: EPS JP¥61.99 (vs JP¥46.72 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥164.3b (up 11% from 3Q 2020). Net income: JP¥7.25b (up 33% from 3Q 2020). Profit margin: 4.4% (up from 3.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.
Analyst Estimate Surprise Post Earnings • Feb 12Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.02%. Earnings per share (EPS) also missed analyst estimates by 5.7%. Over the next year, revenue is forecast to grow 4.5%, compared to a 8.4% growth forecast for the Consumer Retailing industry in Japan.
Is New 90 Day High Low • Dec 04New 90-day high: JP¥4,515The company is up 16% from its price of JP¥3,905 on 04 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥4,276 per share.
お知らせ • Nov 29Sundrug Co.,Ltd. to Report Q3, 2021 Results on Feb 10, 2021Sundrug Co.,Ltd. announced that they will report Q3, 2021 results on Feb 10, 2021
